INTRODUCCIÓN: REVISIÓN CRITICA DEL PROBLEMA

REFERENCIAS BIBLIOGRÁFICAS
314. Hillege H, Van Gilst W, de Zeeuw D, Van Veldhuisen DJ. Renal function as a predictor of
prognosis in chronic heart failure. Heart Fail Monit. 2002;2(3):78-84.
315. Yao D, Brownlee M. Hyperglycemia-Induced Reactive Oxygen Species Increase Expression
of RAGE and RAGE Ligands. Diabetes. 2010 Jan;59(1):249-55.
316. Rabbani N, Sebekova K, Sebekova Jr K, Heidland A, Thornalley PJ. Accumulation of free
adduct glycation, oxidation, and nitration products follows acute loss of renal function.
Kidney Int. 2007 Nov;72(9):1113-21.
317. Jandeleit-Dahm K, Cooper ME. The role of AGEs in cardiovascular disease. Curr Pharm
Des. 2008;14(10):979-86.
318. Meerwaldt R, Links T, Zeebregts C, Tio R, Hillebrands JL, Smit A. The clinical relevance of
assessing advanced glycation endproducts accumulation in diabetes. Cardiovasc
Diabetol. 2008 Oct 7;7:29.
319. Coughlan MT, Mibus AL, Forbes JM. Oxidative stress and advanced glycation in diabetic
nephropathy. Ann N Y Acad Sci. 2008 Apr;1126:190-3.
320. Linden E, Cai W, He JC, Xue C, Li Z, Winston J, Vlassara H, Uribarri J. Endothelial
dysfunction in patients with chronic kidney disease results from advanced glycation end
products (AGE)-mediated inhibition of endothelial nitric oxide synthase through RAGE
activation. Clin J Am Soc Nephrol. 2008 May;3(3):691-8.
321. Levey AS, Eckardt KU, Tsukamoto Y, Levin A, Coresh J, Rossert J, De Zeeuw D, Hostetter
TH, Lameire N, Eknoyan G. Definition and classification of chronic kidney disease: a
position statement from Kidney Disease: Improving Global Outcomes (KDIGO). Kidney
Int. 2005 Jun;67(6):2089-100.
322. Bang H, Vupputuri S, Shoham DA, Klemmer PJ, Falk RJ, Mazumdar M, Gipson D, Colindres
RE, Kshirsagar AV. Screening for Occult REnal Disease (SCORED): a simple prediction
model for chronic kidney disease. Arch Intern Med. 2007 Feb 26;167(4):374-81.
323. Hartog JW, Hummel YM, Voors AA, Schalkwijk CG, Miyata T, Huisman RM, Smit AJ, Van
Veldhuisen DJ. Skin autofluorescence, a measure of tissue advanced glycation endproducts
(AGEs), is related to diastolic function in dialysis patients. J Card Fail. 2008
Sep;14(7):596-602.
324. García Acuña JM, González-Babarro E, Grigorian Shamagian L, Peña-Gil C, Vidal Pérez R,
López-Lago AM, Gutiérrez Feijoó M, González-Juanatey JR. Cystatin C provides more
information than other renal function parameters for stratifying risk in patients with acute
coronary syndrome. Rev Esp Cardiol. 2009 May;62(5):510-9.
325. Hartog JW, Willemsen S, Voors AA. What is the influence of renal function on the prognostic
value of advanced glycation end-products and sRAGE in heart failure? J Card Fail.
2008;14:626.
326. Semba RD, Fink JC, Sun K, Windham BG, Ferrucci L. Serum carboxymethyllysine, a
dominant advanced glycation end product, is associated with chronic kidney disease: the
Baltimore longitudinal study of aging. J Ren Nutr. 2010 Mar;20(2):74-81.
327. Berrou J, Tostivint I, Verrecchia F, Berthier C, Boulanger E, Mauviel A, Marti HP, Wautier
MP, Wautier JL, Rondeau E, Hertig A. Advanced glycation end products regulate
extracellular matrix protein and protease expression by human glomerular mesangial
cells. Int J Mol Med. 2009 Apr;23(4):513-20.
328. Saha SA, Lasalle BK, Clifton GD, Short RA, Tuttle KR. Modulation of advanced glycation
end products by candesartan in patients with diabetic kidney diseasea dose-response
relationship study. Am J Ther. 2010 Nov-Dec;17(6):553-8.
329. Coughlan MT, Thallas-Bonke V, Pete J, Long DM, Gasser A, Tong DC, Arnstein M, Thorpe
SR, Cooper ME, Forbes JM. Combination therapy with the advanced glycation end
product cross-link breaker, alagebrium, and angiotensin converting enzyme inhibitors in
diabetes: synergy or redundancy? Endocrinology. 2007 Feb;148(2):886-95.
330. Macchia A, Levantesi G, Marfisi RM, Franzosi MG, Maggioni AP, Nicolosi GL, Schweiger C,
Tavazzi L, Tognoni G, Valagussa F, Marchioli R; Investigadores del estudio Grupo
243